The role of immunotherapy in multiple myeloma

Nina Shah, MD, University of California, San Francisco, CA, provides her insights on the future of multiple myeloma treatment. Multiple advancements have been made in recent years, especially with the development of immunotherapies. In addition to existing monoclonal antibodies such as daratumumab and isatuximab, chimeric antigen receptor (CAR) T-cell therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) represent alternative therapies for patients with relapsed/refractory multiple myeloma. Dr Shah additionally highlights the development of bispecific T-cell engagers (BiTEs), as well moving immunotherapies into the frontline setting. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.